Company Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States.
The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.
It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers.
In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma.
Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu.
It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH.
The company was founded in 2005 and is based in Princeton, New Jersey.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Dr. Frank K. Bedu-Addo Ph.D. |
Contact Details
Address: 303a College Road East Princeton, New Jersey 08540 United States | |
| Phone | 800-208-3343 |
| Website | pdsbiotech.com |
Stock Details
| Ticker Symbol | PDSB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001472091 |
| CUSIP Number | 70465T107 |
| ISIN Number | US70465T1079 |
| Employer ID | 26-4231384 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Frank K. Bedu-Addo Ph.D. | President, Chief Executive Officer and Director |
| Lars Robert Boesgaard M.B.A. | Principal Financial and Accounting Officer and Chief Financial Officer |
| Dr. Joe J. Dervan | Vice President of Research and Development |
| Dr. Gregory L. Conn Ph.D. | Chief Scientific Officer |
| Deanne Randolph | Head of Investor Relations |
| Spencer Brown J.D. | Senior Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer |
| Dr. Kirk V. Shepard M.D. | Chief Medical Officer |
| Janetta Trochimiuk | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 27, 2024 | 8-K | Current Report |
| Mar 13, 2024 | 8-K | Current Report |
| Jan 29, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 22, 2024 | 8-K | Current Report |
| Dec 4, 2023 | 8-K | Current Report |
| Nov 28, 2023 | 8-K | Current Report |
| Nov 14, 2023 | S-8 | Securities to be offered to employees in employee benefit plans |